Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma

Bibliography

• Frank CJ, McClatchey KD, Devaney KO, Carey TE. Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res 1997;57(5):824-7
   PubMedGoogle Scholar
• Pearlstein RP, Benninger MS, Carey TE, Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 1998;21(4):333-9
   PubMedGoogle Scholar
• Takebayashi S, Ogawa T, Jung KY, Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 2000;60(13):3397-403
   PubMedGoogle Scholar
• Tatemoto K, Rokaeus A, Jornvall H, Galanin – a novel biologically active peptide from porcine intestine. FEBS Lett 1983;164(1):124-8
   PubMedGoogle Scholar
• Leibowitz SF. Regulation and effects of hypothalamic galanin: relation to dietary fat, alcohol ingestion, circulating lipids and energy homeostasis. Neuropeptides 2005;39(3):327-32
   PubMedGoogle Scholar
• Holmes FE, Mahoney SA, Wynick D. Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injury. Neuropeptides 2005;39(3):191-9
   PubMedGoogle Scholar
• Kanazawa T, Iwashita T, Kommareddi P, Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 2007;26(39):5762-71
   PubMedGoogle Scholar
• Kanazawa T, Kommareddi PK, Iwashita T, Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res 2009;15(7):2222-30
   PubMedGoogle Scholar
• Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends Pharmacol Sci 2000;21(3):109-17
   PubMedGoogle Scholar
• Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007;115(2):177-207
   PubMedGoogle Scholar
• Habert-Ortoli E, Amiranoff B, Loquet I, Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci USA 1994;91(21):9780-3
   PubMedGoogle Scholar
• Wang S, Hashemi T, Fried S, Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 1998;37(19):6711-17
   PubMedGoogle Scholar
• Smith KE, Walker MW, Artymyshyn R, Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem 1998;273(36):23321-6
   PubMedGoogle Scholar
• Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14(2):342-6
   PubMed Web of Science ®Google Scholar
• Henson BS, Neubig RR, Jang I, Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem 2005;280(24):22564-71
   PubMedGoogle Scholar
• Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998;273(4):1839-42
   PubMedGoogle Scholar
• Seufferlein T, Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 1996;56(24):5758-64
   PubMedGoogle Scholar
• Mochizuki N, Ohba Y, Kiyokawa E, Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i). Nature 1999;400(6747):891-4
   PubMedGoogle Scholar
• Fathi Z, Cunningham AM, Iben LG, Cloning, pharmacological characterization and distribution of a novel galanin receptor. Brain Res Mol Brain Res 1997;51(1-2):49-59
   PubMedGoogle Scholar
• Smith KE, Forray C, Walker MW, Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem 1997;272(39):24612-16
   PubMedGoogle Scholar
• Wang S, Clemmons A, Strader C, Bayne M. Evidence for hydrophobic interaction between galanin and the GalR1 galanin receptor and GalR1-mediated ligand internalization: fluorescent probing with a fluorescein-galanin. Biochemistry. 1998;37(26):9528-35
   PubMedGoogle Scholar
• Fathi Z, Battaglino PM, Iben LG, Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mol Brain Res 1998;58(1-2):156-69
   PubMedGoogle Scholar
• Wang S, Hashemi T, He C, Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol 1997;52(3):337-43
   PubMedGoogle Scholar
• Hawes JJ, Narasimhaiah R, Picciotto MR. Galanin and galanin-like peptide modulate neurite outgrowth via protein kinase C-mediated activation of extracellular signal-related kinase. Eur J Neurosci 2006;23(11):2937-46
   PubMedGoogle Scholar
• Hobson SA, Holmes FE, Kerr NC, Mice deficient for galanin receptor 2 have decreased neurite outgrowth from adult sensory neurons and impaired pain-like behaviour. J Neurochem 2006;99(3):1000-10
   PubMedGoogle Scholar
• Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem 2007;100(3):780-9
   PubMedGoogle Scholar
• Moelling K, Schad K, Bosse M, Regulation of Raf-Akt Cross-talk. J Biol Chem 2002;277(34):31099-106
   PubMedGoogle Scholar
• Suzuki K, Suzuki I, Leodolter A, Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 2006;9(3):199-207
   PubMedGoogle Scholar
• Iismaa TP, Fathi Z, Hort YJ, Structural organization and chromosomal localization of three human galanin receptor genes. Ann N Y Acad Sci 1998;863:56-63
   PubMed Web of Science ®Google Scholar
• Baylin SB, Ohm JE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6(2):107-16
   PubMedGoogle Scholar
• Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2002;3(12):755-63
   PubMedGoogle Scholar
• Misawa K, Ueda Y, Kanazawa T, Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res 2008;14(23):7604-13
   PubMedGoogle Scholar
• Chung W, Kwabi-Addo B, Ittmann M, Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 2008;3(4):e2079
   Google Scholar
• Bauer FE, Hacker GW, Terenghi G, Localization and molecular forms of galanin in human adrenals: elevated levels in pheochromocytomas. J Clin Endocrinol Metab 1986;63(6):1372-8
   PubMedGoogle Scholar
• Hulting AL, Meister B, Grimelius L, Production of a galanin-like peptide by a human pituitary adenoma: immunohistochemical evidence. Acta Physiol Scand 1989;137(4):561-2
   PubMedGoogle Scholar
• Leung B, Iisma TP, Leung KC, Galanin in human pituitary adenomas: frequency and clinical significance. Clin Endocrinol (Oxf) 2002;56(3):397-403
   PubMedGoogle Scholar
• Bennet WM, Hill SF, Ghatei MA, Bloom SR. Galanin in the normal human pituitary and brain and in pituitary adenomas. J Endocrinol 1991;130(3):463-7
   PubMedGoogle Scholar
• Grenback E, Bjellerup P, Wallerman E, Galanin in pituitary adenomas. Regul Pept 2004;117(2):127-39
   PubMedGoogle Scholar
• Ormandy CJ, Lee CS, Ormandy HF, Amplification, expression, and steroid regulation of the preprogalanin gene in human breast cancer. Cancer Res 1998;58(7):1353-7
   PubMedGoogle Scholar
• Berger A, Lang R, Moritz K, Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology 2004;145(2):500-7
   PubMedGoogle Scholar
• Tjomsland V, El-Salhy M. Effects of single, double or triple combinations of octreotide, galanin and serotonin on a human pancreatic cancer cell line. Histol Histopathol 2005;20(2):537-41
   PubMedGoogle Scholar
• Hammond PJ, Smith DM, Akinsanya KO, Signalling pathways mediating secretory and mitogenic responses to galanin and pituitary adenylate cyclase-activating polypeptide in the 235-1 clonal rat lactotroph cell line. J Neuroendocrinol 1996;8(6):457-64
   PubMedGoogle Scholar
• Iishi H, Tatsuta M, Baba M, Chemoprevention by galanin against colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1995;61(6):861-3
   PubMedGoogle Scholar
• Iishi H, Tatsuta M, Baba M, Inhibition by galanin of experimental carcinogenesis induced by azaserine in rat pancreas. Int J Cancer 1998;75(3):396-9
   PubMedGoogle Scholar
• El-Salhy M, Dennerqvist V. Effects of triple therapy with octreotide, galanin and serotonin on liver metastasis of human colon cancer in xenografts. Oncol Rep 2004;11(6):1177-82
   PubMedGoogle Scholar
• El-Salhy M, Tjomsland V, Theodorsson E. Effects of triple treatment with octreotide, galanin and serotonin on a human pancreas cancer cell line in xenografts. Histol Histopathol 2005;20(3):745-52
   PubMedGoogle Scholar
• McDonald AC, Schuijers JA, Shen PJ, Expression of galanin and galanin receptor-1 in normal bone and during fracture repair in the rat. Bone 2003;33(5):788-97
   PubMedGoogle Scholar
• Takebayashi S, Hickson A, Ogawa T, Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. Genes Chromosomes Cancer 2004;41(2):145-54
   PubMedGoogle Scholar
• Ferbeyre G, de Stanchina E, Lin AW, Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002;22(10):3497-508
   PubMedGoogle Scholar
• Lahlou H, Saint-Laurent N, Esteve JP, sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003;278(41):39356-71
   PubMedGoogle Scholar
• Dixon BS, Evanoff D, Fang WB, Dennis MJ. Bradykinin B1 receptor blocks PDGF-induced mitogenesis by prolonging ERK activation and increasing p27Kip1. Am J Physiol Cell Physiol 2002;283(1):C193-203
   Google Scholar
• Otis M, Campbell S, Payet MD, Gallo-Payet N. Angiotensin II stimulates protein synthesis and inhibits proliferation in primary cultures of rat adrenal glomerulosa cells. Endocrinology 2005;146(2):633-42
   PubMedGoogle Scholar
• Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 1997;94(2):448-52
   PubMedGoogle Scholar
• Tsukada Y, Miyazawa K, Kitamura N. High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 2001;276(44):40968-76
   PubMedGoogle Scholar
• Han J, Tsukada Y, Hara E, Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem 2005;280(36):31548-56
   PubMedGoogle Scholar
• Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78(1):67-74
   PubMedGoogle Scholar
• Esposito V, Baldi A, De Luca A, Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57(16):3381-5
   PubMedGoogle Scholar
• Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005;114(3):406-13
   PubMedGoogle Scholar
• Massarelli E, Brown E, Tran NK, Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 2005;103(5):952-9
   PubMedGoogle Scholar
• Kong S, Amos CI, Luthra R, Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60(2):249-52
   PubMedGoogle Scholar
• Akervall J, Bockmuhl U, Petersen I, The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003;9(5):1750-5
   PubMedGoogle Scholar
• Wittau N, Grosse R, Kalkbrenner F, The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene 2000;19(37):4199-209
   PubMedGoogle Scholar
• Sugimoto T, Seki N, Shimizu S, The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer 2009;48(2):132-42
   PubMedGoogle Scholar
• Tofighi R, Joseph B, Xia S, Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2). Proc Natl Acad Sci USA 2008;105(7):2717-22
   PubMedGoogle Scholar
• Cardone MH, Roy N, Stennicke HR, Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282(5392):1318-21
   PubMedGoogle Scholar
• Zha J, Harada H, Yang E, Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87(4):619-28
   PubMed Web of Science ®Google Scholar
• Shibata MA, Yoshidome K, Shibata E, Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 2001;8(1):23-35
   PubMedGoogle Scholar
• Los M, Stroh C, Janicke RU, Caspases: more than just killers? Trends Immunol 2001;22(1):31-4
   PubMedGoogle Scholar
• Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1(8):639-49
   PubMedGoogle Scholar
• Wang X, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997;15(24):2991-7
   PubMedGoogle Scholar
• Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 2008;98(4):824-31
   PubMedGoogle Scholar
• Putzer BM, Stiewe T, Parssanedjad K, E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ 2000;7(2):177-88
   PubMedGoogle Scholar
• Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004;18(24):3041-54
   PubMedGoogle Scholar
• Wang P, Gao H, Ni Y, Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem 2003;278(8):6363-70
   PubMedGoogle Scholar
• Lasfer M, Vadrot N, Schally AV, Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. J Hepatol 2005;42(2):230-7
   PubMedGoogle Scholar
• Hill SJ. G-protein-coupled receptors: past, present and future. Br J Pharmacol 2006; 147 (Suppl 1):S27-37
   Google Scholar
• Kumar B, Cordell KG, Lee JS, EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26(19):3128-37
   PubMedGoogle Scholar
• Kumar B, Cordell KG, D'Silva N, Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008;134(4):363-9
   PubMedGoogle Scholar
• Yu J, Zhou H, Jin Y, Three distinct regions of allelic deletion on chromosome 17 involved in sporadic gastric cancer. Hepatogastroenterology 2008;55(85):1487-91
   PubMedGoogle Scholar
• Yu JC, Zhou H, Bai J, Human gastric adenocarcinoma allelotype on chromosomes 17 and 18. J Int Med Res 2008;36(2):279-88
   PubMedGoogle Scholar
• Landry M, Holmberg K, Zhang X, Hokfelt T. Effect of axotomy on expression of NPY, galanin, and NPY Y1 and Y2 receptors in dorsal root ganglia and the superior cervical ganglion studied with double-labeling in situ hybridization and immunohistochemistry. Exp Neurol 2000;162(2):361-84
   PubMedGoogle Scholar
• Lundstrom L, Elmquist A, Bartfai T, Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med 2005;7(1-2):157-80
   PubMedGoogle Scholar
• Shen PJ, Larm JA, Gundlach AL. Expression and plasticity of galanin systems in cortical neurons, oligodendrocyte progenitors and proliferative zones in normal brain and after spreading depression. Eur J Neurosci 2003;18(6):1362-76
   PubMedGoogle Scholar
• Mazarati A, Lu X, Kilk K, Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 2004;19(12):3235-44
   PubMedGoogle Scholar
• Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors and drug targets. Cell Mol Life Sci 2008;65(12):1796-805
   PubMedGoogle Scholar
• Bartfai T, Lu X, Badie-Mahdavi H, Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci USA 2004;101(28):10470-5
   PubMedGoogle Scholar
• El-Salhy M, Sitohy B. Triple therapy with octreotide, galanin and serotonin induces necrosis and increases apoptosis of a rat colon carcinoma. Regul Pept 2002;108(2-3):55-62
   PubMedGoogle Scholar
• Merino OR, Lindberg RD, Fletcher GH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1977;40(1):145-51
   PubMedGoogle Scholar
• Clayman GL, el-Naggar AK, Roth JA, In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55(1):1-6
   PubMedGoogle Scholar
• Yoo GH, Moon J, Leblanc M, A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2009;135(9):869-74
   PubMedGoogle Scholar
• Barzon L, Pacenti M, Taccaliti A, A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2005;90(5):2831-4
   PubMedGoogle Scholar
• Gleich LL, Gluckman JL, Nemunaitis J, Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127(7):775-9
   PubMedGoogle Scholar
• Berns KI, Rose JA. Evidence for a single-stranded adenovirus-associated virus genome: isolation and separation of complementary single strands. J Virol 1970;5(6):693-9
   PubMedGoogle Scholar
• Moss RB, Milla C, Colombo J, Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007;18(8):726-32
   PubMed Web of Science ®Google Scholar
• Ozawa K, Fan DS, Shen Y, Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors. J Neural Transm Suppl 2000;(58):181-91
   PubMedGoogle Scholar
• Ishiwata A, Mimuro J, Mizukami H, Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. J Gene Med 2009;11(11):1020-9
   Google Scholar
• Kanazawa T, Mizukami H, Okada T, Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 2003;10(1):51-8
   PubMedGoogle Scholar
• Kanazawa T, Mizukami H, Nishino H, Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells. Int J Oncol 2004;25(3):729-35
   PubMedGoogle Scholar
• Lin EJ, Richichi C, Young D, Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 2003;18(7):2087-92
   PubMedGoogle Scholar
• McCown TJ. Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity. Neurotherapeutics 2009;6(2):307-11
   PubMedGoogle Scholar